Triazolam protein binding and correlation with alpha‐1 acid glycoprotein concentration | Zendy

Kroboth Patricia D | Zendy; Smith Randall B | Zendy; Sorkin Michael I | Zendy; Silver Marcia R | Zendy; Rault Raymond | Zendy; Garry Michael | Zendy; Juhl Randy P | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Triazolam protein binding and correlation with alpha‐1 acid glycoprotein concentration

Author(s) -

Kroboth Patricia D,

Smith Randall B,

Sorkin Michael I,

Silver Marcia R,

Rault Raymond,

Garry Michael,

Juhl Randy P

Publication year - 1984

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1038/clpt.1984.191

Subject(s) - triazolam , chemistry , orosomucoid , albumin , hypnotic , chromatography , plasma concentration , clinical pharmacology , plasma protein binding , dialysis , serum albumin , pharmacology , endocrinology , medicine , glycoprotein , biochemistry , benzodiazepine , receptor

On two occasions separated by a minimum of 1 wk, plasma was obtained from 12 patients (aged 18 to 73 yr) on dialysis after an overnight fast. Samples were assayed for albumin and α 1 ‐acid glycoprotein (AGP) concentrations. 14 C‐Triazolam was added to each sample to a final concentration of 5 ng/ml. Protein binding was determined by equilibrium dialysis. Unbound triazolam ranged from 6.4% to 15.4% (X̄ = 10.0%). AGP concentrations ranged from 71.8 to 205.1 mg% (X̄ = 123.4 mg%). Triazolam binding ratio (bound/unbound concentration) correlated with AGP concentration (r 2 = 0.69) but not with albumin concentration, age, or sex. This correlation was verified by adding AGP in varying amounts to control plasma. Clinical Pharmacology and Therapeutics (1984) 36, 379–383; doi: 10.1038/clpt.1984.191

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research